Read by QxMD icon Read

ki67 residual breast cancer

Paula Cabrera-Galeana, Wendy Muñoz-Montaño, Fernando Lara-Medina, Alberto Alvarado-Miranda, Victor Pérez-Sánchez, Cynthia Villarreal-Garza, R Marisol Quintero, Fany Porras-Reyes, Enrique Bargallo-Rocha, Ignacio Del Carmen, Alejandro Mohar, Oscar Arrieta
BACKGROUND: Several breast cancer (BC) trials have adopted pathological complete response (pCR) as a surrogate marker of long-term treatment efficacy. In patients with luminal subtype, pCR seems less important for outcome prediction. BC is a heterogeneous disease, which is evident in residual tumors after neoadjuvant-chemotherapy (NAC). This study evaluates changes in Ki67 in relation to disease-free survival (DFS) and overall survival (OS) in patients without pCR. SUBJECTS, MATERIALS, AND METHODS: Four hundred thirty-five patients with stage IIA-IIIC BC without pCR after standard NAC with anthracycline and paclitaxel were analyzed...
February 28, 2018: Oncologist
Lingmin Xie, Xiaolei Li, Qinchuan Wang, Jichun Zhou, Jun Shen, Lixi Luo, Yi Lu, Linbo Wang
Objectives: The aim of our study is to evaluate the effect of core needle biopsy (CNB) and subsequent neoadjuvant chemotherapy (NAC) on the expression of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth hormone receptor 2 (HER2) and Ki67 in breast cancer, and the associated influencing factors. Materials and methods: In this retrospective cohort study, 143 patients with primary operable breast cancer who received NAC were included. ER, PR, HER2 and Ki67 statuses were compared between pretreatment and posttreatment residual samples...
2018: OncoTargets and Therapy
Isabel Echavarría, Sara López-Tarruella, Antoni C Picornell, Jose A Garcia-Saenz, Yolanda Jerez-Gilarranz, Katherine A Hoadley, Henry Gomez, Fernando Moreno, Maria Del Monte-Millán, Ivan Marquez-Rodas, Enrique L Alvarez, Rocío Ramos-Medina, Javier Gayarre, Tatiana Massarrah, Inmaculada Ocaña, María Cebollero, Hugo Fuentes, Agustí Barnadas, Ana Isabel Ballesteros, Uriel Bohn, Charles M Perou, Miguel Martín
PURPOSE: Triple-negative breast cancer (TNBC) requires the identification of reliable predictors of response to neoadjuvant chemotherapy (NACT). For this purpose, we aimed to evaluate the performance of the TNBCtype-4 classifier in a cohort of TNBC patients treated with neoadjuvant carboplatin and docetaxel (TCb). METHODS: TNBC patients were accrued in a non-randomized trial of neoadjuvant carboplatin AUC 6 and docetaxel 75 mg/m2 for 6 cycles. Response was evaluated in terms of pathological complete response (pCR, ypT0/is ypN0) and residual cancer burden by Symmans et al...
January 29, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Caitlin Murphy, Violet Mukaro, Robert Tobler, Rebecca Asher, Emma Gibbs, Linda West, Bruno Giuffre, Sally Baron-Hay, Mustafa Khasraw
BACKGROUND: Magnetic Resonance Imaging (MRI) accuracy after neoadjuvant systemic therapy (NST) for breast cancer varies according to hormone receptor (HR), human epidermal growth factor receptor type-2 (HER2) subtype and Ki67 proliferation index. Whether MRI accuracy varies by genomic signatures is unknown. We examined accuracy of MRI in the NEONAB trial ( #: NCT01830244). METHODS: Patients with stage II-III breast cancer received sequential epirubicin, cyclophosphamide and nab-paclitaxel and trastuzumab if HER2+...
September 4, 2017: Internal Medicine Journal
Jasna Trifunovic, Numa Memisevic, Borislava Nikolin, Svetlana Salma, Tihomir Dugandzija, Vladimir Vidovic
PURPOSE: To evaluate the changes in biological markers ER, PR, HER2 and Ki67 in residual tumor after surgery for locally advanced breast cancer (LABC), and also to evaluate the outcome of breast cancer patients treated with neoadjuvant chemotherapy (NAC). METHODS: 144 breast cancer patients treated with NAC at the Oncology Institute of Vojvodina, Serbia from 2011 to 2015 were included in this study. Changes in biologic markers ER,PR, HER2/neu and Ki-67 were evaluated at diagnostic core biopsy and at the final surgery tissue specimens...
May 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
A Sheri, I E Smith, M Hills, R L Jones, S R Johnston, M Dowsett
AIMS: To determine whether IHC4 score assessed on pre-treatment core biopsies (i) predicts response to neo-adjuvant chemotherapy in ER-positive (ER+) breast cancer; (ii) provides more predictive information than Ki67 alone. METHODS: 113 patients with ER+ primary breast cancer treated with neo-adjuvant chemotherapy at the Royal Marsden Hospital between 2002 and 2010 were included in the study. Pathologic assessment of the excision specimen was made for residual disease...
July 2017: Breast Cancer Research and Treatment
Xiaoqing Jia, Guangyu Liu, Jingyi Cheng, Zhenzhou Shen, Zhimin Shao
BACKGROUND: Studies have demonstrated that cysteine-rich 61 (CYR61) may be involved in tumor proliferation and invasion. However, the role of CYR61 plays in endocrine therapy response is largely unknown. PATIENTS AND METHODS: We tested the levels of CYR61 expression of 36 primary breast cancer patients who received neo-adjuvant endocrine therapy for at least 3 months by immunohistochemistry staining before and after administrating letrozole, an oral non-steroidal aromatase inhibitor (AI) for the treatment of hormone-responsive breast cancer...
2017: Current Cancer Drug Targets
Yukie Enomoto, Takashi Morimoto, Arisa Nishimukai, Tomoko Higuchi, Ayako Yanai, Yoshimasa Miyagawa, Keiko Murase, Michiko Imamura, Yuichi Takatsuka, Takashi Nomura, Masashi Takeda, Takahiro Watanabe, Seiichi Hirota, Yasuo Miyoshi
BACKGROUND: Residual cancer burden or Ki67 expression levels in residual tumors reportedly provided significant prognostic information for a non-pathological complete response subset after neoadjuvant chemotherapy (NAC). However, the significance of Ki67 reduction for clinical response during chemotherapy in each subtype or menopausal status is yet to be determined. METHODS: A total of 183 breast cancers surgically removed after chemotherapy were recruited for this study...
April 2016: International Journal of Clinical Oncology
Belinda Yeo, Mitch Dowsett
Neoadjuvant endocrine treatment has become of increasing interest for downstaging primary ER+ breast cancers as it has become clear that the pathologic complete response rate of luminal tumours to chemotherapy is much lower than that of non-luminal and differs little from that to endocrine therapy. There is much more experience in postmenopausal than premenopausal women. Aromatase inhibitors are generally the agent of choice. Responses are lower in those with the low levels of ER. While duration of endocrine treatment in clinical trials has usually been standardized at around three to four months it is clear that volume reductions continue to occur beyond that time in a large proportion of cases and routine clinical practice is often to treat to maximum response...
November 2015: Breast: Official Journal of the European Society of Mastology
Valentina Guarneri, Maria Vittoria Dieci, Antonio Frassoldati, Antonino Maiorana, Guido Ficarra, Stefania Bettelli, Enrico Tagliafico, Silvio Bicciato, Daniele Giulio Generali, Katia Cagossi, Giancarlo Bisagni, Samanta Sarti, Antonino Musolino, Catherine Ellis, Rocco Crescenzo, PierFranco Conte
BACKGROUND: The CHER-LOB randomized phase II study showed that the combination of lapatinib and trastuzumab plus chemotherapy increases the pathologic complete remission (pCR) rate compared with chemotherapy plus either trastuzumab or lapatinib. A biomarker program was prospectively planned to identify potential predictors of sensitivity to different treatments and to evaluate treatment effect on tumor biomarkers. MATERIALS AND METHODS: Overall, 121 breast cancer patients positive for human epidermal growth factor 2 (HER2) were randomly assigned to neoadjuvant chemotherapy plus trastuzumab, lapatinib, or both trastuzumab and lapatinib...
September 2015: Oncologist
Amit Agrawal, John F R Robertson, Kwok L Cheung, Eleanor Gutteridge, Ian O Ellis, Robert I Nicholson, Julia M W Gee
We report the first study of the biological effect of fulvestrant on ER positive clinical breast cancer using sequential biopsies through to progression. Thirty-two locally/systemically advanced breast cancers treated with first-line fulvestrant (250 mg/month) were biopsied at therapy initiation, 6 weeks, 6 months and progression and immunohistochemically-analyzed for Ki67, ER, EGFR and HER2 expression/signaling activity. This series showed good fulvestrant responses (duration of response [DoR] = 25.8 months; clinical benefit = 81%)...
January 1, 2016: International Journal of Cancer. Journal International du Cancer
Marie Klintman, Mitchell Dowsett
The assessment of new therapies in the adjuvant setting in early breast cancer requires large numbers of patients and many years of follow-up for results to be presented. Therefore, the neoadjuvant study setting, which allows for early prediction of treatment response in smaller patient sets, has become increasingly popular. Ki67 is the most commonly used and extensively studied intermediate biomarker of treatment activity and residual risk in neoadjuvant trials on endocrine therapy, new biological therapies, and chemotherapy...
May 2015: Journal of the National Cancer Institute. Monographs
Flavio Crippa, Roberto Agresti, Marco Sandri, Gabriella Mariani, Barbara Padovano, Alessandra Alessi, Giulia Bianchi, Emilio Bombardieri, Ilaria Maugeri, Mario Rampa, Maria Luisa Carcangiu, Giovanna Trecate, Claudio Pascali, Anna Bogni, Gabriele Martelli, Filippo de Braud
PURPOSE: We evaluated whether (18)F-3'-deoxy-3'-fluorothymidine positron emission tomography (FLT PET) can predict the final postoperative histopathological response in primary breast cancer after the first cycle of neoadjuvant chemotherapy (NCT). METHODS: In this prospective cohort study of 15 patients with locally advanced operable breast cancer, FLT PET evaluations were performed before NCT, after the first cycle of NCT, and at the end of NCT. All patients subsequently underwent surgery...
May 2015: European Journal of Nuclear Medicine and Molecular Imaging
Qi-Xing Tan, Qing-Hong Qin, Wei-Ping Yang, Qin-Guo Mo, Chang-Yuan Wei
BACKGROUND: Immunohistochemical (IHC) expression of Ki67 has been identified as a prognostic and predictive marker in hormone receptor (HR)-positive breast cancer, however, there is little evidence of the association of Ki67 with prognosis in HR-negative patients. We aimed to assess the benefit of Ki67 assessment in HR-negative breast cancers after neoadjuvant chemotherapy (NAC). METHODS: In the present study, a total of 183 HR-negative breast cancer patients with Stage II to III that treated with anthracycline and/or taxane-based neoadjuvant chemotherapy between 2004 and 2011 were retrospectively analyzed...
2014: International Journal of Clinical and Experimental Pathology
A Sheri, I E Smith, S R Johnston, R A'Hern, A Nerurkar, R L Jones, M Hills, S Detre, S E Pinder, W F Symmans, M Dowsett
BACKGROUND: The purpose of this study was (i) to test the hypothesis that combining Ki67 with residual cancer burden (RCB) following neoadjuvant chemotherapy, as the residual proliferative cancer burden (RPCB), provides significantly more prognostic information than either alone; (ii) to determine whether also integrating information on ER and grade improves prognostic power. PATIENTS AND METHODS: A total of 220 patients treated with neoadjuvant chemotherapy for primary breast cancer were included in the study...
January 2015: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Haixia Jia, Weijuan Jia, Yaping Yang, Shunrong Li, Huiyi Feng, Jieqiong Liu, Nanyan Rao, Liang Jin, Jiannan Wu, Ru Gu, Liling Zhu, Kai Chen, Heran Deng, Yunjie Zeng, Qiang Liu, Erwei Song, Fengxi Su
BACKGROUND: The effect of breast cancer subtype on margin status after lumpectomy remains unclear. This study aims to determine whether approximated breast cancer subtype is associated with positive margins after lumpectomy, which could be used to determine if there is an increased risk of developing local recurrence (LR) following breast-conserving surgery. METHODS: We studied 1,032 consecutive patients with invasive cancer who received lumpectomies and cavity margin (CM) assessments from January 2003 to November 2012...
2014: World Journal of Surgical Oncology
Agnieszka K Witkiewicz, Derek Cox, Erik S Knudsen
In spite of the efficacy of Her2-targeted therapies, recurrence and progression remain a challenge for treatment of Her2 positive breast cancer. CDK4/6 controls pathway downstream of Her2, Inhibition of these kinases could represent an important therapeutic approach to augment the effectiveness of standard therapies. In models of acquired resistance to Her2-targeted therapies, Cyclin D1 was inappropriately activated and CDK4/6 inhibition was effective at blocking proliferation by targeting this common pathway associated with resistance...
July 2014: Genes & Cancer
Muhammad Alamgeer, Vinod Ganju, Beena Kumar, Jane Fox, Stewart Hart, Michelle White, Marion Harris, John Stuckey, Zdenka Prodanovic, Michal Elisabeth Schneider-Kolsky, D Neil Watkins
INTRODUCTION: Although neoadjuvant chemotherapy (NAC) for locally advanced breast cancer can improve operability and local disease control, there is a lack of reliable biomarkers that predict response to chemotherapy or long-term survival. Since expression of aldehyde dehydrogenase-1 (ALDH1) is associated with the stem-like properties of self-renewal and innate chemoresistance in breast cancer, we asked whether expression in serial tumor samples treated with NAC could identify women more likely to benefit from this therapy...
April 24, 2014: Breast Cancer Research: BCR
Amy S Clark, Jinbo Chen, Shiv Kapoor, Claire Friedman, Carolyn Mies, Laura Esserman, Angela DeMichele
Laboratory studies suggest that vitamin D (vitD) enhances chemotherapy-induced cell death. The objective of this study was to determine whether pretreatment vitD levels were associated with response to neoadjuvant chemotherapy (NACT) in women with breast cancer. Study patients (n = 82) were enrolled on the I-SPY TRIAL, had HER2-negative tumors, and available pretreatment serum. VitD levels were measured via DiaSorin radioimmunoassay. The primary outcome was pathologic residual cancer burden (RCB; dichotomized 0/1 vs...
June 2014: Cancer Medicine
Maria Afentakis, Mitch Dowsett, Ivana Sestak, Janine Salter, Tony Howell, Aman Buzdar, John Forbes, Jack Cuzick
BAG1 is a multifunctional anti-apoptotic protein located on chromosome 9q12, which binds to Bcl-2. BAG1 is present as a separate module in the GHI-RS 21-gene panel. It may provide additional prognostic information as an immunohistochemical marker when added to IHC4. Analysis of BAG1 was performed on archival tumour blocks from patients from the anastrozole and tamoxifen arms of the ATAC trial of 5 years endocrine therapy in postmenopausal women with oestrogen receptor (ER)-positive primary breast cancer. Staining was scored separately as nuclear or cytoplasmic...
July 2013: Breast Cancer Research and Treatment
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"